News
Why DexCom Stock Is Crashing Today
Shares of DexCom (NASDAQ: DXCM) were crashing 39.9% lower as of 10:20 a.m. ET on Friday. The huge sell-off came after the continuous glucose monitoring (CGM) systems maker announced its
Better Buy: Abbott Laboratories vs. Intuitive Surgical
Investors looking for stocks that can go up want to turn their heads toward the medical technology industry. Demand for devices that enable minimally invasive surgical procedures and remote
DexCom (DXCM) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q2 2024 Earnings CallJul 25, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and
Why AbbVie Stock Was Cruising Higher on Thursday
AbbVie (NYSE: ABBV) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AbbVie (NYSE: ABBV)Q2 2024 Earnings CallJul 25, 2024, 9:00 a.m. ET
Operator
Source Fool.com
Why Viking Therapeutics Stock Is Skyrocketing Today
Shares of Viking Therapeutics (NASDAQ: VKTX) were skyrocketing 32.3% as of 11:21 a.m. ET on Thursday. The big gain came after the clinical-stage biopharmaceutical company provided its second-quarter
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q2 2024 Earnings CallJul 25, 2024, 6:45 a.m. ET
Operator
Source Fool.com
Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed
Got $5,000? These 3 Growth Stocks Are Incredibly Cheap Buys Right Now
Buying quality growth stocks doesn't have to involve paying an enormous premium. There are some solid, underrated companies worth buying right now that don't trade at egregious valuations. While
Is AbbVie the Best Dividend Stock for You?
It was great while it lasted, but AbbVie's (NYSE: ABBV) most important cash cow -- rheumatoid arthritis treatment Humira -- has been out of patent exclusivity in the U.S. since last year. That's not
AT&T Impresses With Subscriber Growth and Free Cash Flow
Coming a few days after a mixed earnings report from rival Verizon Communications, AT&T's (NYSE: T) second-quarter report suffered from a similar problem. Wireless customers have been slow to
3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years
If you're looking for some good dividend stocks to own in retirement, one thing you'll want to focus on is stability. Striking a balance between safety and dividend income can be key to ensuring you
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
If you're looking to invest in order to get richer, that's great -- because most of us need to be amassing a war chest for retirement (not to mention other financial goals, such as a down payment
Beware, Wegovy -- Pfizer Is Working on a Competitor
Which company is the leader in the burgeoning weight loss drug market? A recent poll found that among the largest drugmakers, Pfizer (NYSE: PFE) is the one Americans associate most with this
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant
EQS-News: Drägerwerk AG & Co. KGaA: Dräger on track to meet annual forecast after a solid first half-year
Why AT&T Stock Is Rising Today
Shares of the telecommunications giant AT&T (NYSE: T) popped this morning after the company released second-quarter results showing strong subscriber growth and impressive free cash flow.
AT&T's
AT&T; (T) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AT&T (NYSE: T)Q2 2024 Earnings CallJul 24, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Humana Healthy Horizons Commits to Increasing Healthcare Access for Oklahomans
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), is investing in community-based organizations throughout Oklahoma to expand access
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
If there's one thing healthcare giant Pfizer (NYSE: PFE) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are
This Ultra-High-Yield Dividend Stock Hits Yet Another Setback
Medical Properties Trust (NYSE: MPW) has been struggling because of tenant issues, which has made it more difficult for the real estate investment trust (REIT) to manage its large debt load. The
Why Arm Holdings Stock Is Jumping Today
Arm Holdings (NASDAQ: ARM) stock is advancing in Tuesday's trading. The semiconductor company's share price was up 5% as of 3 p.m. ET, according to data from S&P Global Market Intelligence.
While
This 6%-Yielding Dividend Stock Is About to Get a Boost From the Biggest IPO of 2024
Lineage Logistics, a real estate investment trust (REIT) focused on cold storage facilities, is preparing to go public. It's seeking to raise up to $3.9 billion -- a $19.2 billion valuation --
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar